Oral agent shows durable improvement in SUI patients

San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.